DMACDiaMedica Therapeutics Inc
DMAC
DiaMedica Therapeutics Inc1,556
Mkt Cap
$349.16MVolume
94,267.0052W High
$10.4252W Low
$3.19PE Ratio
-9.28DMAC Fundamentals
Price
$6.64Prev Close
$6.48Open
$6.5750D MA
$7.79Beta
1.19Avg. Volume
232,456.98EPS (Annual)
-$0.6974P/B
6.21Rev/Employee
$0.00$314.32
Q1 EPS Estimate for DiaMedica Therapeutics Raised by Analyst
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Free Report) - Stock analysts at HC Wainwright raised their Q1 2026 earnings per share estimates for DiaMedica Therapeutics in a report released on Wednesday, April 1st. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($0.17) per...
MarketBeat·3d ago
HC Wainwright Issues Pessimistic Estimate for DMAC Earnings
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Free Report) - Research analysts at HC Wainwright reduced their FY2029 EPS estimates for DiaMedica Therapeutics in a research note issued to investors on Wednesday, April 1st. HC Wainwright analyst M. Caufield now expects that the company will post earning...
MarketBeat·4d ago
DiaMedica Therapeutics Q4 Earnings Call Highlights
DiaMedica Therapeutics (NASDAQ:DMAC) executives used the company's fiscal 2025 earnings call on Monday to highlight clinical progress for its lead asset DM199 and review an improved year-end cash position following financing activity in 2025.
DM199 mechanism and pipeline focus
President and CEO Ric...
MarketBeat·6d ago
DiaMedica Therapeutics (NASDAQ:DMAC) Posts Earnings Results, Beats Expectations By $0.02 EPS
DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.02...
MarketBeat·7d ago
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR), and acute ischemic...
Business Wire·7d ago
Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings
DiaMedica Therapeutics (NASDAQ: DMAC) will release Q4 earnings on March 30. Analysts expect a quarterly loss of 18 cents per share. Stock fell 0.9% on Friday.read more...
Benzinga·7d ago
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Average Rating of "Moderate Buy" by Brokerages
Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) have received a consensus rating of "Moderate Buy" from the six brokerages that are covering the firm, MarketBeat Ratings...
MarketBeat·8d ago
DiaMedica Therapeutics (DMAC) Projected to Post Earnings on Tuesday
DiaMedica Therapeutics (NASDAQ:DMAC) will be releasing its Q4 2025 earnings on Tuesday, March 31. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-31-diamedica-therapeutics-inc-stock...
MarketBeat·14d ago
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke...
Business Wire·14d ago
Cooperman Leon G Raises Position in DiaMedica Therapeutics, Inc. $DMAC
Cooperman Leon G lifted its holdings in DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Free Report) by 98.2% in the third quarter, according to its most recent filing with the Securities and Exchange...
MarketBeat·22d ago
<
1
2
...
>